Specify a stock or a cryptocurrency in the search bar to get a summary
Phathom Pharmaceuticals Inc
PHATPhathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Address: 100 Campus Drive, Florham Park, NJ, United States, 07932
Analytics
WallStreet Target Price
25.29 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PHAT
Dividend Analytics PHAT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PHAT
Stock Valuation PHAT
Financials PHAT
Results | 2019 | Dynamics |